Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,067 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: azuma k. J Hepatol. 2013 Oct;59(4):667-74. doi: 10.1016/j.jhep.2013.05.017. Epub 2013 May 23. J Hepatol. 2013. PMID: 23707372 Clinical Trial.
Body surface area is an independent factor contributing to the effects of lamivudine treatment.
Nakamuta M, Kotoh K, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Furusyo N, Nomura H, Sakai H, Takahashi K, Azuma K, Shimoda S, Enjoji M, Hayashi J; Kyushu University Liver Disease Study Group. Nakamuta M, et al. Among authors: azuma k. Hepatol Res. 2005 Jan;31(1):13-17. doi: 10.1016/j.hepres.2004.11.004. Epub 2004 Dec 28. Hepatol Res. 2005. PMID: 15652465
Relationship between body surface area and ALT normalization after long-term lamivudine treatment.
Nakamuta M, Morizono S, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Furusyo N, Nomura H, Sakai H, Takahashi K, Azuma K, Shimoda S, Kotoh K, Enjoji M, Hayashi J; Kyushu University Liver Disease Study Group. Nakamuta M, et al. Among authors: azuma k. World J Gastroenterol. 2005 Nov 28;11(44):6948-53. doi: 10.3748/wjg.v11.i44.6948. World J Gastroenterol. 2005. PMID: 16437598 Free PMC article.
Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.
Furusyo N, Takeoka H, Toyoda K, Murata M, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Nomura H, Nakamuta M, Takahashi K, Shimoda S, Azuma K, Sakai H, Hayashi J. Furusyo N, et al. Among authors: azuma k. World J Gastroenterol. 2006 Jan 28;12(4):561-7. doi: 10.3748/wjg.v12.i4.561. World J Gastroenterol. 2006. PMID: 16489669 Free PMC article.
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group.
Furusyo N, Katoh M, Tanabe Y, Kajiwara E, Maruyama T, Shimono J, Sakai H, Nakamuta M, Nomura H, Masumoto A, Shimoda S, Takahashi K, Azuma K, Hayashi J; Kyushu University Liver Disease Study Group. Furusyo N, et al. Among authors: azuma k. World J Gastroenterol. 2006 Feb 7;12(5):784-90. doi: 10.3748/wjg.v12.i5.784. World J Gastroenterol. 2006. PMID: 16521196 Free PMC article. Clinical Trial.
Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group.
Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Masumoto A, Maruyama T, Nakamuta M, Enjoji M, Azuma K, Shimono J, Sakai H, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Furusyo N, et al. Among authors: azuma k. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1094-104. doi: 10.1111/j.1440-1746.2008.05319.x. Epub 2008 Feb 3. J Gastroenterol Hepatol. 2008. PMID: 18248381 Clinical Trial.
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.
Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J; Kyushu University Liver Disease Study Group. Kainuma M, et al. Among authors: azuma k. World J Gastroenterol. 2010 Sep 21;16(35):4400-9. doi: 10.3748/wjg.v16.i35.4400. World J Gastroenterol. 2010. PMID: 20845506 Free PMC article. Clinical Trial.
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group. Ogawa E, et al. Among authors: azuma k. J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x. J Gastroenterol Hepatol. 2012. PMID: 22098185 Clinical Trial.
1,067 results